“Melanotan” signals its design goal — the melanocortin/melanin system — and the Roman numeral II marks it as a second analog in the series.

It is a laboratory-designed molecule, so the name reflects intent (acting on melanocortin receptors) rather than a natural substance. Melanotan II is a modified, cyclized relative of the natural hormone fragment alpha-MSH.

Melanotan II is a small cyclic peptide analog — a ring of seven residues based on the active core of alpha-MSH.

It is built around the alpha-MSH message sequence but incorporates modifications — including a D-amino acid and the norleucine (Nle) substitution — and is cyclized to make it more stable and potent than the natural fragment. Because it contains non-standard residues, its structure is described rather than quoted as a plain natural-amino-acid string.

Melanotan II came out of academic melanocortin chemistry at the University of Arizona.

Researchers there studied alpha-MSH, the natural peptide that stimulates pigment-producing cells, and set out to engineer more stable and potent analogs of it. Melanotan II emerged from that structure-activity work as a cyclized, modified agonist of the melanocortin receptor family.

The rationale was to fix the weaknesses of the natural hormone fragment.

Native alpha-MSH is rapidly broken down and short-acting. By substituting residues and cyclizing the peptide, the designers aimed for a molecule that resisted degradation, held its active shape, and bound melanocortin receptors more strongly. Melanotan II is non-selective, engaging multiple melanocortin receptor subtypes rather than a single one.

Melanotan II is produced by solid-phase peptide synthesis, including the extra chemistry needed for its ring and modified ends.

The chain is assembled on resin using the specified natural and non-natural residues, the N-terminal acetyl and C-terminal amide are installed, and a lactam bridge is formed to cyclize the molecule. It is then cleaved, deprotected and purified by HPLC, with mass spectrometry confirming identity.

Melanotan II is a real research compound in melanocortin pharmacology, and its honest status here is strictly investigational reference.

It has been studied as a melanocortin agonist tool, and its non-selective receptor activity is well documented in the literature. This does not amount to any endorsement of use: the material is research-use-only, is not approved for human use, is not medical advice, and no dose, timing or protocol is provided. Melanotan II is also a compound where unsupervised human use has raised documented safety concerns, which is a further reason it is presented here only as reference science. Direct any human-use questions to a licensed physician.